Pceut532_Exam1_2008 Key

Pceut532_Exam1_2008 Key - ./ PHARMACEUTICS 532 Winter 2008...

Info iconThis preview shows pages 1–8. Sign up to view the full content.

View Full Document Right Arrow Icon
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Background image of page 2
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Background image of page 4
Background image of page 5

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Background image of page 6
Background image of page 7

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Background image of page 8
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: ./ PHARMACEUTICS 532 Winter 2008 Midterm #1 I January 25th Néme Kaz ' I I Student # Questions v Points 1 15 2 5 3- ‘ 16 4- JP 5 4 ‘ 6 15 1. (15 points) Check the appropriate answer a.The well-stirred model of the liver describes hepatic clearance as: a]: =g—f”—CZ—m—. Based on this model Q ‘+ 12%: -Enzyme induction will increase the hepatic clearance of a high extraction ratio drug ' 3P1} ~ > True False K _ Decreased plasma protein binding will increase the hepatic clearance of low extraction ratio drug - 3 W} True False -Hepatic extraction ratio is defined as CL*Q 3 01373 ‘ True ' False X . I-Pharmacokinetic (enzyme;_kinetic) parameters determined in vitrocan be scaled (extrapolated) to in vivo clearance. “ . " 0’73 True False - A drug with high hepatic clearance will have an extraction ratio of 7-10. 3P7.) True False X ' 2. (5 points) Belbw is unbound fractiondata for three drugs. Predict the rank order ’ of their volumes of distribution (Rank them based on V as lowest, medium and highest, an empty column is provided to present any calculations you may need) lb f 0 01 6;: m Wm Wm 3. (16 points) Calculate the following values. Please show the equations you used ' to obtain the values in your answer. After a 5.6 mg/kg i.v.dose theophylline kinetics can be described by the equation: . 70 K _ _ #5561 L fi- 6 J) :3 2M9— 5.8t 0.16t '4 0056 g: 70k ? Concentration is given in units of ug/mL and time in hours. Calculate - a. The volume of distribution of the entral co Pirtment for theo hylline Vc . ” = /3-l b. The distribution half-life for theo ‘ a. 60/ 3 -_ 0. f3 ‘ 575’ — -. 0. Plasma concentration of theophylline 3 hours after-thew. dose —£&(:D - .(J) — C4 ‘ ’35 H a a! ( = 35z’l'laq1-ll.) JIM”;th d. The AUC of theophylline ’4‘46"; A+_B__ )Z-M "I +’/.5’A)ZJ~I _ a; ,, 1;- x ' first The pharmacokinetics of procainamide follow a 2-Compaftmen'tn‘i0d'el. LT I‘ ’ "The therapeutic and toxic effects of procainamide 'are associated with the central or compartment 1. Based on the following pharmacokinetic parameters, calculate a loading dose(s) in order to target a therapeutic concentration of 6 mall. in a .50 kg patient. ' V1: 0.7 L/kg VB = 2.0 L/kg 7—67,.) pa“ = TD : is 2 2969‘” T1/2a=5min T1/2B=3h1‘ ‘ m S = 0.87 procainamide HCL ' 2;]: F = bioavailability = 1.0 for IV TDLJfi 7A.; =3 630mg. Therapeutic range: 4-8 mg/L __ , LD=V*C - Acadia»; 0052. l : [D : __ 0.7%9I5v1z3Y6h-3/ F *S a r I I: ‘5 Qflhg, anal-2115‘; 401‘— L 670 " m = may I NM (5m) CW Wu st gay/L ' .1052 3 chfi‘dzM—CW; (0.7%9X3D/9)[[~w£‘5a;fl)_‘20 7w . W 150mg» ‘4’“ few??? C : 5.77/4. 005:2} Rea/MA.- ~ 250*“; @ 170 a IYO ha}, @— t;3~h‘h~ _ 57w) (4 pts) The pharmacokinetics of digoxin follows a 2—compartment model. The gm; therapeutic and toxic effects of digoxin‘are associated with the Eerie/mat [ compartment. Therefore, after a complete loading dose, the digoxin serum - concentration obtained immediately after dosing will be 413 45/ 9673 than the recommended therapeutic range (15 pts) The frames below depict a plasma concentration-time curves for a drug after an iv. dose of 100 mg; Using the same frames and the space provided next to each one of them sketch how the curve would look and how CL, V, Co, t1/2 and AUC would change in each case if I ~ a. The clearance (CL) of the drug doubled CD :- Nc: Cbt‘amfl logC , T72. 1 ‘1’ 23‘ k V : Neal‘wa time b. The volume of distribution (V) doubled s?‘ 31' A 3? [MAC - No charge. 6" :_ N0 almané—L 7. (35 pts) A 54 kg woman was given a _4 mg/kg iv-bolus of an antibiotic. Plasma concentrations of the antibiotic were measured as follows: Time hours Plasma con entration m /L ~ )— o.25 ( ) 8 C .( g )9352 :GV/Qéqk; “QM”? 1.0 ' . - 7 6 , 3 12 5 1 a. 'Using the graph paper provided on the next page, draw the, plasma "concentration-time curve of this drug. Write the equation that best describes the plasma-concentration of this drug in this patient as a function of time. a - 0.18117 a _— S». Li a b. Calculate the values for volume of distribution and t1/2. VI : '2— :. 22,6335: = I _ 0.673_ a575_ 17%“ K 7 44k. ',. 36] iv; o. This antibiotic has a minimuminhibitory concentratio'ntMl'C) in plasma thatris ~ mg/L. What is thefduration‘o'f activity ’of this ‘d‘rug‘ inithis patient? - r -o.1$'( -6 . . ’ 2 mg/Hsfi‘té 9 D =a Jim/0110C): .0"m_9_ , 'm m ’x w 8”” _F vamp 1;:777463gA/5 d. If the dose was doubled what would be-the duration of activity and half-life? ‘er ate/awn car: (Jami, ml 59, lac/fayax 57- OM& tYL (“L/1V5) .57 fifaufllfi’} 74% date. *j’zlerdvre/ we new Aux-M as aunt/at, writ. .5e, w )9 IV; 11/275 Mmmyx £7 flé§a IIIIIIlgllgIEl55M!IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII EIIIEEIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII IIi!!!lIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII . IIIIII.llIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII “ I; ‘I n_“ .5. Va _: — — _ — — — — — _ _ — _ _ _ _ — — _ _ _ — _ _ — _ — — — — — _ — _ — — — — — ‘l I * “"lllll , u I I ‘ — IiIIIII Iiillill III... 'uNIIIIIIIIIIIIIIIIIIIIIIIIIIIIII!IIIIIIIIIIIIIIIIIIE!!IIIIIIIIg; Hf] IIIIIillIIIIIIIIIIIIIIIIIIIIIEIIEIEIIEIIEIIIllllllllillillll*~ ‘IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIi!!!II ,- IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII!! O 1 2 3 4 6 A 7 8 9 1O 11 12 13 14 1 tyl'w (4/) 5 Equations D A V—a—E _Cu_ 1 f“_—t_1+Ka.[P] V=w+w§§i Vp=3L,Vt=39L t dA a —kA 0:06.84“ 02 Z 01 O 8_k(t2—tl) Dose ' V Q: lnC’ ——§ lnC’d—kt 4 D D VP 53 " A+B D ‘@=:AUC.5 B mm=é+— oz fl 0.693 1/22? D OlflAUO 0.693.V 1/2: V90 L17:— F08 (15) ...
View Full Document

Page1 / 8

Pceut532_Exam1_2008 Key - ./ PHARMACEUTICS 532 Winter 2008...

This preview shows document pages 1 - 8. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online